Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to partner with other Big Pharma names?

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, ...

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Wegovy, which is a prescription medicine is indicated to help manage weight and lower the risk of serious heart-related ...